Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making.
Phase of Trial: Phase II/III
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Girentuximab Zr-89 (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 16 Jun 2017 Status changed from recruiting to completed.
- 19 Sep 2016 New trial record